OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic Data from its First-In-Human PIKture-01 Trial of OKI-219
| OKUR Stock | 8.52 0.08 0.93% |
Slightly above 63% of OnKure Therapeutics,'s investor base is looking to short. The analysis of overall sentiment of trading OnKure Therapeutics, stock suggests that many investors are alarmed at this time. OnKure Therapeutics,'s investing sentiment overview a quick insight into current market opportunities from investing in OnKure Therapeutics,. Many technical investors use OnKure Therapeutics, stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
OnKure |
-- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinical models -- Data support the initiation of Part 1b of PIKture-01 evaluating OKI-219 in combination with fulvestrant first patients dosed, and initial data are expected in 2H-2025 -- Management to host conference call today, December 10, 2024 at 700
Read at finance.yahoo.com
 |
OnKure Therapeutics, Fundamental Analysis
We analyze OnKure Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OnKure Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OnKure Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
OnKure Therapeutics, is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
OnKure Therapeutics, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with OnKure Therapeutics, stock to make a market-neutral strategy. Peer analysis of OnKure Therapeutics, could also be used in its relative valuation, which is a method of valuing OnKure Therapeutics, by comparing valuation metrics with similar companies.
Peers
OnKure Therapeutics, Related Equities
| VIRX | Viracta Therapeutics | 10.56 | ||||
| VIGL | Vigil Neuroscience | 4.12 | ||||
| VRNA | Verona Pharma | 3.81 | ||||
| VRDN | Viridian Therapeutics | 3.03 | ||||
| VKTX | Viking Therapeutics | 2.06 | ||||
| VRCA | Verrica Pharmaceuticals | 0.96 | ||||
| VNDA | Vanda Pharmaceuticals | 0.63 | ||||
| VCNX | Vaccinex | 0.91 | ||||
| DWTX | Dogwood Therapeutics, | 1.20 |
Additional Tools for OnKure Stock Analysis
When running OnKure Therapeutics,'s price analysis, check to measure OnKure Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OnKure Therapeutics, is operating at the current time. Most of OnKure Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of OnKure Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OnKure Therapeutics,'s price. Additionally, you may evaluate how the addition of OnKure Therapeutics, to your portfolios can decrease your overall portfolio volatility.